Triple positivity refers to the presence of three specific biomarkers in breast cancer: oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) positivity. This classification is clinically significant as it influences treatment decisions, often leading to targeted therapies that improve outcomes. A key association is that triple-positive breast cancers may exhibit more aggressive behaviour, necessitating comprehensive management strategies.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.